Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Trial Profile

Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Sotatercept (Primary) ; Dexamethasone; Lenalidomide; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 18 Nov 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 18 Nov 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.
    • 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top